- Home
- TIXT vs GHRS Comparison
TIXT vs GHRS Comparison
Compare TIXT & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TIXT
- GHRS
- Stock Information
- Founded
- TIXT 2005
- GHRS 2018
- Country
- TIXT Canada
- GHRS Ireland
- Employees
- TIXT N/A
- GHRS N/A
- Industry
- TIXT EDP Services
- GHRS Biotechnology: Pharmaceutical Preparations
- Sector
- TIXT Technology
- GHRS Health Care
- Exchange
- TIXT Nasdaq
- GHRS Nasdaq
- Market Cap
- TIXT 1.1B
- GHRS 960.2M
- IPO Year
- TIXT 2021
- GHRS 2021
- Fundamental
- Price
- TIXT $3.85
- GHRS $13.98
- Analyst Decision
- TIXT Hold
- GHRS Strong Buy
- Analyst Count
- TIXT 8
- GHRS 8
- Target Price
- TIXT $3.82
- GHRS $30.63
- AVG Volume (30 Days)
- TIXT 606.0K
- GHRS 353.0K
- Earning Date
- TIXT 08-01-2025
- GHRS 09-02-2025
- Dividend Yield
- TIXT N/A
- GHRS N/A
- EPS Growth
- TIXT N/A
- GHRS N/A
- EPS
- TIXT N/A
- GHRS N/A
- Revenue
- TIXT $2,671,000,000.00
- GHRS N/A
- Revenue This Year
- TIXT $4.29
- GHRS N/A
- Revenue Next Year
- TIXT $3.32
- GHRS N/A
- P/E Ratio
- TIXT N/A
- GHRS N/A
- Revenue Growth
- TIXT N/A
- GHRS N/A
- 52 Week Low
- TIXT $2.13
- GHRS $6.00
- 52 Week High
- TIXT $6.86
- GHRS $20.50
- Technical
- Relative Strength Index (RSI)
- TIXT 53.23
- GHRS 45.60
- Support Level
- TIXT $3.97
- GHRS $12.81
- Resistance Level
- TIXT $4.16
- GHRS $15.26
- Average True Range (ATR)
- TIXT 0.14
- GHRS 1.51
- MACD
- TIXT -0.03
- GHRS -0.40
- Stochastic Oscillator
- TIXT 34.04
- GHRS 17.46
About TIXT TELUS International (Cda) Inc. Subordinate Voting Shares
TELUS International (Cda) Inc is a digital customer experience innovator that designs, builds, and delivers next-generation solutions. Its clients include companies across several verticals, including Tech and Games, eCommerce and FinTech, Banking, Financial Services and Insurance, Communications and Media, and Healthcare. The solutions offered by the company include Digital Experience, Customer Experience, Advisory Services, and Back Office and Automation among other services. Geographically, it derives a majority of its revenue from the European region.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.